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Summary.-Monoclonal antibodies to carcinoembryonic antigen (CEA) promise
improved specificity for the measurement of this widely expressed human cancer
antigen. A mouse monoclonal antibody binds weakly to CEA in perchloric acid
extracts of tumour but strongly to CEA similarly isolated from serum, and its
spectrum of cancer detection differs from conventional antisera.
METHODS in somatic cell hybridization,
introduced by Kohler & Milstein (1975),
have made it possible to produce mono-
clonal antibodies in tissue culture. Whilst
the method has proved entirely successful
for the production of antibodies against
particulate antigens such as those on the
cell surface (Trucco et al., 1978) and viruses
(Koprowski et al., 1977), it has only re-
cently been successfully applied to soluble
tumour markers such as CEA (Accolla et
al., 1979), hCG (Stahli et al., 1980) and
alpha-foetoprotein (Tsung et al., 1980).
Monoclonal antibodies against CEA are
of special interest, since they promise to
overcome particular difficulties associated
with the antigenic heterogeneity of this
glycoprotein (Rogers, 1976). Conventional
antisera raised to purified CEA, even after
removal of antibodies to known cross-
reactive antigens such as NCA, contain a
mixed population of antibodies (Keep &
Rogers, 1979; Rogers & Keep, 1980).
Different batches of antisera consequently
vary in binding affinity for different forms
of CEA or different antigens in the pre-
paration, and this may impair or alter
clinical specificity ofthe CEA assay. Mono-
clonal anti-CEA on the other hand should
be able to discriminate between small anti-
genic differences expressed by the CEA
complex, and provide tools to characterize
CEA immunologically, to optimize and
stabilize the specificity of the CEA assay
and to test the concept that some antigenic
1
determinants on CEA or in CEA prepara-
tions may be of more clinical relevance as
tumour markers than others (Rogers,
1976). Here we describe the first mono-
clonal antibodies with a high specificity
for circulating CEA.
In this study BALB/c mice were
immunized with 40 ,ug of highly purified
CEA (R42), followed by a similar boost
5 weeks later (R42 was isolated by
perchloric acid extraction of a pool of 6
metastatic colonic tumours as described
previously Rogers et al., 1976). After
removal of red cells by lysis, 108 spleen
cells from these mice were fused with 107
mouse myeloma cells (P3-NSL/lAg 4-1,
Flow Laboratories) in polyethylene glycol
according to the method of Kohler &
Milstein (1975) and distributed into 180
microtitre wells. The next day the medium
was replaced with medium containing
hypoxanthine, aminopterin and thym-
idine, in which only hybrid cells remained
viable. Supernatants from wells containing
actively growing hybrid cells were then
tested for anti-CEA activity by means
of binding to 1251-labelled CEA using
a double-antibody radioimmunoassay
method. Antibody producing cells were
cloned by dilution or single-cell transfer
and viable cells propagated. 107 anti-
CEA producing cells were injected i.p. into
BALB/c mice to obtain ascites fluid MA-1
and serum MS-1.
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TABLE I.-Percentage binding of mono-
clonal antibody MA-1 to increasing con-
centrations of radiolabelled CEA
Concentration
oflabel
x I
x 2
x 3
x 4
Total
ct/min
205480
466550
587127
804214
Bound counts
Ct/min %
23736 11 55
48948 10-49
68728 11-70
93904 1160
MS-1 were carried out using radio-labelled
1251-CEA (R42). This was prepared by
labelling 20 ,ug of the CEA protein with
5 mCi of IMS 30, according to a modified
method of Greenwood et al. (1963). The
iodinated CEA was purified on Sephadex
G-200 and the fractions with maximum
binding to our conventional anti-CEA
serum selected. The labelled CEA was used
at a dilution of 1:200, equivalent to
200,000 ct/min.
Binding studies with MA-1 and MS-1
showed that at a dilution of 1:1000 they
were able to bind 110% and 170% of 0 3 ng
of 1251-CEA (50 pi of diluted label) using
an optimum dilution of 1:4 for the pre-
cipitating antibody (goat-anti-mouse).
Maximum binding at a dilution of 1:100
was 2700, in contrast with the much
greater binding (700%) achieved at this
dilution with both conventional anti-CEA
(PKIG) and the monoclonal sera described
by Accolla et al. (1979). The percentage
binding of MA-1 at 1:1000 to 1251-CEA
was found to be constant (I1I%) and inde-
pendent of the concentration of label
(Table I). This indicates that the MA-1
antibodies bind to a small sub-population
of CEA molecules present in the label, or
alternatively that the binding affinity was
so low that as more label was added more
of it bound to the antibody. These inter-
pretations are consistent with other
studies on the competitive binding of
purified unlabelled CEA. In these experi-
ments increasing amounts of standard
CEA (R43, prepared in a similar manner
to CEA-R42 but from a different pool of
metastatic colonic tumours) were incu-
bated with a mixture ofmonoclonal serum
A -: _t,2sj .,.
I27 '- -,-ll S l
FIGURE. Comparative inhibition of 12511
CEA-MS-1 by CEA purified from perchloric
acld extracts of 3 different pools (each
comprising specimens from 6 patients) of
liver metastases from colonic tumour (A, B,
C) from a saline extract ofaliver metastases
from a single patient with a rectal tumour
(D) and from a perchloric acid extract of a
pool of 11 sera from patients with cancer
and a raised CEA value (E). The CEA
concentrations were measured in ng/ml by
our conventional CEA assay. Curve C shows
the inhibition in the range 360-10,000 ng/
ml of CEA (R43) which has been used as
standard for the assays developed with
monoclonal antibodies MS-1 and MA-1.
For conx-enience an arbitrary unit has been
adopted whereby 100 u/ml of MS-1 binding
CEAproduce500% "displacement" ofbound
label and are equix alent to 8600 ng/ml of
conventional CEA.
at 1:1000 dilution, the radiolabelled CEA
and a commercial rabbit anti-mouse pre-
cipitating antibody (Dako Z109 at 1:40
dilution). It was demonstrated that a con-
centration of 8600 ng/ml of CEA was
required to produce 5000 "inhibition" of
bound label (Figure). The concentrations
of CEA in ng/ml for these studies were
measured by our routine CEA assay, using
a conventional absorbed anti-CEA serum
PK1G.
In comparison, a similar inhibition in
our routine assay is produced by only
40 ng ofCEA. Further studies have shown
that 3 additional preparations of purified
tumour CEA are comparatively poor
inhibitors of the monoclonal MS--1 25J
CEA system, requiring concentrations of
CEA in excess of 8000 ng/ml to produce
5000 displacement ofbound label (Figure).
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TABLE II.-Content of MS-1 binds
in saline, perchloric acid and he
saline extracts of the metastat
tumour described in the Figure,
ated by Con A-Sepharose
chromatography
Con A
fraction
1
2A
2B
3
4
CEA in crude
extract
Recovery %
Saline
extract
37 0
4-9
10-3
18-7
55.0
229-0
54 0
HCLO4
extract
7-6
11-0
100-0
8-4
3-4
238-0
55*0
* For details see Keep et al. (1978).
values are expressed in u/g of wet tissue o
measuring the fractions on a double-anti
developed with the monoclonal serum A
Because ofthe poor inhibition by
CEA preparations an arbitrary
has been adopted for use in radio
assay with MS-I and MA-1. Thus
MS-1 binding CEA are defined
amount producing 50% displac
bound label.
Preliminary radioimmunoassai
ments developed with MS-1 have
marked loss ofbinding activity oi
a saline extract of liver meta,
rectal tumour at 85°C for 30 mi
II), demonstrating that the deti
with which MS-1 binds is present
heat-labile and heat-stable n
Further studies with extracts
tumours are required to see whe
is general, though similar findi]
recently been obtained on a v
CEA extracts, using conventional
(Keep & Rogers, 1979). Like con
anti-CEA, MS-1 is also unable t
guish different chemical forms
separated by concanavalin A
chromatography. In these pr
experiments, liver metastases of
tumour was extracted (a) with
acid, (b) with saline and (c) with s
subsequently heat-treated at 85'
min. Each extract was applied to
of con A-Sepharose and eluted v
ing CEA sodium acetate containing IM NaCl (Frac-
at-treated tion 1), 01M sodium borate in 0dIM
ic rectal phosphate buffer pH 6-0 (Fraction 2A);
fraction- the remaining fractions 2B, 3 and 4 were
affinity eluted respectively with 2%, 10% and
20% methyl glucoside in the acetate
Heat- buffer as described elsewhere (Keep et al.,
treated 1978). Each fraction was then assayed in a
extract double-antibody assay developed with
47 6 MS-1. The presence of MS-1 binding CEA
205 was demonstrated in all fractions (Table
1o04 II) suggesting that the MS-1 binding
16 0 determinant is not affected by hetero-
990 geneity of the carbohydrate residues in
55r0 CEA, and is probably situated in the
internal part of the CEA glycoprotein
The CEA (Rogers, 1976). Studies with several per-
btained by chloric acid extracts of tumour CEA have body assay
IS-1. shown that the Con A-binding profile of
MS-i-binding CEA is similar to that
standard obtained with conventional CEA where
unitage verylittle non-binding CEA isfound (Keep
immuno- et al., 1978). However, in contrast to the
100 u of results with perchloric acid extracts, a
as that significant fraction of MS-i-binding CEA,
ement of isolated by saline extraction of tumour at
neutral pH, was not bound by Con A-
y experi- Sepharose (Table II). This difference has
shown a been seen previously with foetal colon
n heating CEA, but not with tumour CEA, using
stases of conventional antisera (Keep et al., 1978)
in (Table and further suggests that MS-1 may be
,erminant specific for a unique sub-population of
t on both CEA molecules, possibly of foetal type.
nolecules. Nine normal-tissue extracts tested, in-
of other cluding a lung, a liver, a spleen and 6
-ther this colon extracts all from separate indi-
ngs have viduals, contain very little MS-i-binding
-ariety of antigen with values ranging from 1 8-4-9
1 antisera u/g oftissue. It is significant that extracts
ventional of normal spleen and lung, which contain
to distin- a high content of the normal cross-
of CEA reacting antigen NCA, do not inhibit the
affinity MS-1-1251-CEA binding any more strongly
eliminary than the normal colon extracts, showing
' a rectal that the specificity of MS-1 is probably
)erchloric not directed to NCA.
,aline and In contrast to CEA extracted from
°C for 30 tumour tissue, CEA isolated by perchloric
a column acid extraction of a pool of II sera from
vith 01m patients with advanced colonic cancer
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"displaced" the MS-i-bound label easily
(Figure). In this case the serum CEA,
measured as 1000 ng/ml on our routine
assay, produced "displacement" in the
monoclonal system in excess of 80%. This
suggests that serum CEA either has a
larger sub-population of MS-1-binding
CEA or has a higher overall binding
affinity for MS-I than is found in CEA
extracted from tumours. These differences
could result from chemical modifications
of CEA by extraction from the serum of
cancer patients or by the predominance in
the serum of CEA which has been de-
graded or altered in the liver. The latter is
more likely, since double-antibody radio-
immunoassays developed with mono-
clonal sera have confirmed the high
specificity of both MS-1 and MA-1 for a
CEA component in untreated sera from
patients with various cancers. Thus 30/102
(29%) ofsamples from patients with colon
cancer, 16/42 (38%) of samples from
patients with rectal cancer, 16/31 (51%)
of samples from patients with gastric
cancer and 12/34 (35%) of patients with
prostatic cancer produced raised values
(> 15 u/ml). Of 144 samples from normal
subjects, only one was raised. Compared
to CEA assays with conventional antisera,
the "monoclonal" assays were much less
sensitive to CEA extracted from tumour
tissue.
The results described here demonstrate
that monoclonal antibodies bind to an
antigen present in highly purified CEA
from various tumours and with our radio-
labelled CEA as used in our routine assay.
They are also consistent with the concept
that different immunological forms of
CEA exist which can be distinguished by
appropriate antisera. However, in view of
the immunological heterogeneity of CEA
and the polyspecific nature of many con-
ventional anti-CEA sera (Rogers & Keep,
1980) we cannot exclude the possibility
that these monoclonal sera are recognizing
a unique antigen not related to CEA, but
present in purified CEA preparations. If
this is the case the antigen is clearly
related to malignancy since it is prevalent
in the serum of patients with cancer but
not detected in significant amounts in sera
from normal individuals and extracts of
normal lung, spleen, liver and colon. The
study suggests that the deployment of
different monoclonal sera raised against
purified CEA may help to establish
whether some antigenic determinants in
these preparations are ofparticular clinical
interest.
Support of the Medical Research Council is grate-
fully acknowledged.
REFERENCES
ACCOLLA, R. S., CARNEL, S., PHAN, M., HENMANN,
D. & MACH, J. P. (1979) First report of the
production of Somatic cell hybrids secreting
monoclonal antibodies specific for carcinoembry-
onic antigen (CEA). Protide& Biol. Fluids, 27, 31.
GREENWOOD, F. C., HUNTER, W. M. & GLOVER, J. S.
(1963) The preparation of 1311-labelled growth
hormone of high specific activity. Biochem. J.,
89, 114.
KEEP, P. A., LEAKE, B. A. & ROGERS, G. T. (1978)
Extraction of CEA from tumour tissue, foetal
colon and patients' sera, and the effect of per-
chloric acid. Br. J. Cancer, 37, 171.
KEEP, P. A. & ROGERS, G. T. (1979) Heat-labile
CEA. Protide8 Biol. Fluids, 27, 41.
K6HLER, G. & MILSTEIN, C. (1975) Continuous
cultures of fused cells secreting antibody of pre-
defined specificity. Nature, 256, 495.
KoPRowsKI, M., GERHARD, W. & CROCE, C. M. (1977)
Production of antibodies against influenza virus
by somatic cell hybrids between mouse myeloma
and primed spleen cells. Proc. Natl Acad. Sci.,
U.S.A., 74, 2985.
ROGERS, G. T. (1976) Heterogeneity of carcino-
embryonic antigen: Implications on its role as a
tumour marker substance. Biochem. Biophys.
Acta, 458, 355.
ROGERS, G. T., SEARLE, F. & BAGSHAWE, K. D.
(1976) Carcinoembryonic antigen: Isolation of a
sub-fraction with high specific activity. Br. J.
Cancer, 33, 357.
ROGERS, G. T. & KEEP, P. A. (1980) CEA-like
activity in normal colon tissue. Eur. J. Cancer,
16, 127.
STAHLI, C., STAEHELIN, T., MIGGIANo, V., SCHMIDT,
J. & HARING, P. (1980) High frequencies of
antigen-specific hybridomas: Dependence on
immunization parameters and prediction by
spleen cell analysis. J. Immunol. Methods, 32, 297.
TRUCCO, M. M., STOCKER, J. W. & CAPPELLINI, R.
(1978) Monoclonal Antibodies against human
lymphocyte antigens. Nature, 273, 666.
TSUNG, Y-K., MILUNSKY, A. & ALPERT, E. (1980)
Secretion by a hybridoma of antibodies against
human of fetoprotein. N. Engl. J. Med., 302, 180.